Study Title

Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/ CT in Patients with Orbital Neoplasms and Compared with 18F-FDG PET/ CT

Study Details

Description:

To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in orbital neoplasms, and compared with 18F-FDG PET/CT.

Sponsor:

Peking University First Hospital

Contacts:

Lingge Suo

suolingge_1019@126.com

86-010-82264935

Hui Li

huilee1990@163.com

86-010-82264935

Government Study Link:

NCT06791226 - Click here to see study on

ClinicalTrials.gov

Drug Details

18F-AlF-FAPI
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • FAP

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468